MyMyelomaTeam

For people with low-risk MGUS, the progression risk is about 1% per year. Risk factors that can affect progression include M protein levels above 15 g/L, specific types of M proteins (IgA, IgM, or IgD), and abnormal free light chain ratios in the blood. Regular monitoring is essential for MGUS patients. Your healthcare team Show Full Answer

For people with low-risk MGUS, the progression risk is about 1% per year. Risk factors that can affect progression include M protein levels above 15 g/L, specific types of M proteins (IgA, IgM, or IgD), and abnormal free light chain ratios in the blood. Regular monitoring is essential for MGUS patients. Your healthcare team will typically schedule follow-up appointments every 6-12 months to check for any changes or progression. This monitoring includes blood tests to evaluate protein levels and assess progression risk. Given the complexity of your situation with both MGUS and breast cancer, it would be advisable to discuss your specific concerns about radiation therapy with both your hematologist and oncologist. They can evaluate your individual risk factors and provide guidance based on your complete medical profile.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Multiple Myeloma Types and Related Conditions

MGUS vs. Multiple Myeloma: What’s the Difference? (VIDEO)